Loading clinical trials...
Loading clinical trials...
A Multicenter, Double-blind, Parallel-group Comparative Study Between Oral BAYA1040_CR 80 mg and 40 mg for 8 Weeks in Patients With Essential Hypertension for Whom Oral BAYA1040_CR 40 mg is Insufficient
Conditions
Interventions
Nifedipine (Adalat, BAYA1040)
Nifedipine (Adalat, BAYA1040)
Locations
22
Japan
Hirosaki, Aomori, Japan
Kamagaya, Chiba, Japan
Asahikawa, Hokkaido, Japan
Asahikawa, Hokkaido, Japan
Sapporo, Hokkaido, Japan
Sapporo, Hokkaido, Japan
Start Date
January 1, 2011
Primary Completion Date
August 1, 2011
Completion Date
August 1, 2011
Last Updated
January 29, 2014
NCT02417740
NCT07480265
NCT07073820
NCT06876233
NCT06062394
NCT06899815
Lead Sponsor
Bayer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions